Reference is made to the notice of Extraordinary General Meeting distributed to the shareholders of Nordic Nanovector AS on
In accordance with the proposals set out in the notice, the Extraordinary General Meeting has today resolved to issue 10 million new shares in the Private Placement at a price of
The subsequent share issue will be directed towards the shareholders of the Company as of
If not all subscription rights are used by the eligible holders, then the remaining shares may be subscribed to by the shareholders of the Company as of
The Company will prepare a prospectus in connection with the subsequent share issue. The subscription period in the subsequent share issue will not commence until the prospectus is approved by the
The Company expects that the prospectus will be approved by the NFSA in late
The Extraordinary General Meeting also resolved the other matters on the agenda in accordance with the proposals of the Board of Directors, as further set out in the attached minutes of the Extraordinary General Meeting.
Tone KvÅle, CFO Phone: ( 47) 22 18 33 01 Cell: ( 47) 91 51 95 76 Fax: ( 47) 22 58 00 07 E-mail: firstname.lastname@example.org About Nordic Nanovector AS Nordic Nanovector AS is a privately held company established in 2009. The company is based in
About Betalutin Betalutin™, is a pharmaceutical product candidate consisting of a radionuclide conjugated to a tumor seeking carrier/antibody, which can be used for irradiation of malignant metastasized tumors with minimal damage to nearby healthy normal tissue. This technology aims to prolong and improve the quality of life of people who suffer from non-Hodgkin Lymphoma (NHL).
IMPORTANT NOTICE: This announcement is not and does not form a part of any offer for sale of securities.
Copies of this announcement are not being made and may not be distributed or sent into
The securities referred to in this announcement have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and accordingly may not be offered or sold in
This announcement is not a prospectus for the purposes of Directive 2003/71/EC (together with any applicable implementing measures in any Member State, the “Prospectus Directive”). Investors should not subscribe for any securities referred to in this announcement except on the basis of information contained in the aforementioned prospectus. In any EEA Member State other than
This communication is only being distributed to and is only directed at persons in the
The information, opinions and forward-looking statements contained in this announcement speak only as at its date, and are subject to change without notice.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Most Popular Stories
- National Retail Federation Reduces Sales Forecast
- Hispanic Leader Goes the Extra Mile
- Xavier Gutierrez Appointed to Bank Board
- Ted Cruz: Why Did FAA Ban Flights to Israel?
- Honda' s Accord Plug-in Hybrid Is a Fuel Miser
- Morgan Stanley Ponies Up $275 Million to Settle SEC Charges
- Stop-Start Engines Save Gas, Reduce Emissions
- Long-term Strengths Emerge in U.S. Economy
- Risks of Layoffs Becoming Rarer in U.S.
- Weekly Jobless Claims Drop to Lowest Level in 8 Years